Form 4: Xilio CEO Rene Russo Reports Equity Changes

Xilio Therapeutics CEO Rene Russo reported the acquisition of 44,250 common shares from RSU conversion and a grant of 1,500,258 stock options.

Summary

• Rene Russo, President and CEO of Xilio Therapeutics, Inc., reported changes in beneficial ownership.
• Acquired 44,250 shares of common stock on January 1, 2026, through the conversion of Restricted Stock Units (RSUs).
• Following this transaction, Russo directly owns 325,422 shares of common stock.
• Received a grant of 1,500,258 stock options (Tranche 3 Options) on December 31, 2025, with an exercise price of $0.841 per share and an expiration date of October 7, 2035.
• These options were granted on October 8, 2025, subject to stockholder approval of the 2025 Stock Incentive Plan, which was obtained on November 21, 2025.
• A portion of the Tranche 3 Options met performance criteria on December 31, 2025, tied to Series B Warrants and Non-Dilutive Capital.
• The stock options vest in three equal annual installments starting December 31, 2025, contingent on continued service.
• Russo also holds 88,500 Restricted Stock Units directly, which were granted on January 1, 2024, and vest in four equal annual installments beginning January 1, 2025.

Sentiment

Score: 7

Explanation: The filing reports routine executive equity compensation and the achievement of performance criteria for a portion of new stock options, which is generally positive for management alignment and suggests progress on capital structure initiatives. No negative information is present.

Positives

• The grant of 1,500,258 stock options to the CEO indicates continued incentive and alignment with company performance.
• A portion of the Tranche 3 Options met performance criteria by December 31, 2025, suggesting achievement of specific company milestones related to Series B Warrants and Non-Dilutive Capital.
• Stockholder approval of the 2025 Stock Incentive Plan on November 21, 2025, demonstrates shareholder support for the company's long-term incentive strategy.

Risks

• The vesting of Tranche 3 Options is subject to the CEO's continued service, posing a risk if the CEO departs.
• The performance criteria for Tranche 3 Options are tied to the exercise/cancellation of Series B Warrants due to Non-Dilutive Capital, indicating reliance on future capital events.

Future Outlook

The company's 2025 Stock Incentive Plan, approved by stockholders, provides a framework for future equity compensation. The vesting of new stock options is tied to future performance criteria related to Series B Warrants and Non-Dilutive Capital, indicating a focus on capital structure and financing events.

Industry Context

This Form 4 filing reflects standard executive compensation practices in the biotechnology or pharmaceutical industry, where equity grants like stock options and restricted stock units are common tools to incentivize leadership and align their interests with long-term shareholder value. The mention of 'Non-Dilutive Capital' and 'Series B Warrants' suggests the company is actively managing its capital structure, a common theme for development-stage biotech firms.

Comparison to Industry Standards

• Equity compensation for CEOs, including stock options and RSUs, is a standard practice across the biotech and broader public company landscape, comparable to practices at companies like Moderna or BioNTech for incentivizing leadership.
• The structure of performance-based vesting tied to specific financial or operational milestones (e.g., Non-Dilutive Capital, Series B Warrants) is a common mechanism to ensure executive compensation is aligned with company success, similar to performance share units seen at larger pharmaceutical companies.
• The exercise price of $0.841 for the options is typical for grants made at or near the market price on the grant date, a common practice to provide future upside potential.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of performance-based options to the CEO aligns management incentives with shareholder value creation. The approval of the 2025 Stock Incentive Plan provides a mechanism for future equity-based compensation.
• Employees: The 2025 Stock Incentive Plan likely provides a broader framework for employee equity compensation, though this filing specifically details CEO grants.

Next Steps

• Continued vesting of the 1,500,258 stock options in three equal annual installments beginning December 31, 2025, subject to continued service.
• Continued vesting of the remaining 88,500 Restricted Stock Units in annual installments beginning January 1, 2025.

Key Dates

Recommendation

This Form 4 primarily details routine executive equity compensation, including the conversion of RSUs and the grant of new performance-based stock options. While the achievement of performance criteria for a portion of the options is a positive signal regarding capital structure management, and the overall compensation structure aligns management incentives, the filing does not contain information significant enough to warrant a 'buy' or 'sell' recommendation. It's a standard disclosure of insider transactions, suggesting a 'hold' position as it doesn't fundamentally alter the investment thesis.

Keywords

Xilio Therapeutics, XLO, Rene Russo, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, CEO Compensation, Beneficial Ownership, Stock Incentive Plan